U.S. Medical Equipment Stock News

NasdaqGM:CHRS
NasdaqGM:CHRSBiotechs

Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline?

Coherus Oncology, Inc. recently filed a prospectus supplement allowing it to sell up to US$64.88 million of common stock through an at-the-market offering, shortly after Oppenheimer began covering the company with an Outperform rating based on its oncology pipeline. The focus on the anti-CCR8 antibody tagmokitug and the PD-1 inhibitor Loqtorzi highlights how investors are weighing pipeline potential against ongoing capital needs. We’ll now examine how this combination of fresh equity...
NasdaqGM:ALT
NasdaqGM:ALTBiotechs

Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...
NasdaqCM:PANL
NasdaqCM:PANLShipping

Why Pangaea Logistics Solutions (PANL) Is Up 21.8% After Beating Estimates On Arctic Fleet Strength

Pangaea Logistics Solutions recently reported a strong past quarter, with revenue topping analyst expectations and adjusted EBITDA rising on the back of active Arctic trade and heavy use of its specialized ice-class fleet. This operational strength, which stood out against marine transportation peers, has drawn increased attention to Pangaea’s niche positioning in higher‑barrier shipping routes. Next, we’ll explore how this earnings beat and the company’s high ice-class fleet utilization...
NasdaqGS:CASH
NasdaqGS:CASHBanks

Pathward Financial Buybacks And New Model Accompany Undervalued Growth Story

Pathward Financial reported strong Q1 results, including higher net income and earnings per share. The company introduced a new operating model focused on optimizing relationships with its partners. Management also completed a significant share repurchase program, which may indicate confidence in the business. For investors watching NasdaqGS:CASH, these updates come alongside a share price of $85.72 and multi year returns that have been positive, including 19.3% year to date and 126.1% over...
NasdaqGM:NAMM
NasdaqGM:NAMMMetals and Mining

Assessing Namib Minerals (NAMM) Valuation After A Sharp Unexplained Share Price Surge

Volatility in Namib Minerals after unexplained price spike Namib Minerals (NAMM) has drawn fresh attention after a share price jump of more than 100% on January 21, 2026, despite no new company announcements or regulatory filings. The move coincided with stronger gold prices during ongoing geopolitical tensions. This appears to have attracted short-term speculative interest and raised questions about liquidity risk and price sustainability. See our latest analysis for Namib Minerals. The...
NasdaqGS:PAX
NasdaqGS:PAXCapital Markets

The Bull Case For Patria Investments (PAX) Could Change Following Upward Estimates And Fundraising Momentum - Learn Why

In January 2026, Patria Investments hosted its PAX Talks IV call, focusing on “Investing Amidst Ugly Geopolitics” while analysts highlighted its favorable growth profile and upwardly revised earnings estimates. Against a backdrop of rising institutional demand for alternative assets, Patria’s repeated increases to fundraising guidance and strong fee-earning inflows have reinforced confidence in its long-term growth engine. We’ll now examine how Patria’s upward earnings estimate revisions and...